Poor
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment with the FDA label is limited. The evaluation supports only a subset of the claims (primarily indications and bleeding risk with anticoagulants) and contains multiple unsupported statements. Key label domains (contraindications/boxed warnings, pregnancy, pediatric use) are omitted.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing icosapent ethyl, a highly purified omega-3 fatty acid.
1 Indications and Usage
Vascepa is approved by the FDA for reducing triglycerides in adults with severe hypertriglyceridemia.
1 Indications and Usage
Increased risk of bleeding: Omega-3 fatty acids, including those found in Vascepa, may increase the risk of bleeding, particularly in patients taking anticoagulant medications.
5.3 Bleeding; 7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents
Vascepa may increase the risk of bleeding.
5.3 Bleeding; 7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents
The recommended dosage of Vascepa is 4 grams per day, taken orally.
2 Dosage and Administration
Unsupported Statements
Nausea and vomiting: Up to 10% of patients may experience nausea and vomiting, usually mild and temporary.
Not provided with a frequency or description in the label; gastrointestinal adverse events are mentioned but not with this frequency/characterization.
Abdominal pain: Mild abdominal pain has been reported in up to 5% of patients.
No frequency claim of up to 5% in label.
Diarrhea: Diarrhea has been reported in up to 3% of patients.
No frequency claim of up to 3% in label.
Increased risk of liver damage: High doses of omega-3 fatty acids have been linked to liver damage in some studies.
No liver toxicity claim in labeled sections provided.
Potential impact on kidney function: Some research suggests that omega-3 fatty acids may have a negative impact on kidney function in patients with pre-existing kidney disease.
No kidney function risk statement in the cited label sections.
Amarin Corporation, the manufacturer of Vascepa, has responded to concerns about long-term side effects by stating that the medication has been extensively studied in clinical trials and has a well-established safety profile.
Not reflected in the cited label sections.
Some experts have raised concerns about the lack of long-term data on the medication's safety.
Not reflected in the cited label sections.
Dr. Steven Nissen, a cardiologist and expert in cardiovascular medicine, has expressed concerns about the long-term safety of Vascepa.
Not reflected in the cited label sections.
Vascepa may cause liver damage.
No liver toxicity warning in the cited label sections.
Vascepa may have a potential impact on kidney function.
No explicit kidney function risk in the cited label sections.
Patients with pre-existing kidney disease should consult with their doctor before taking Vascepa, as it may have a negative impact on kidney function.
No kidney-specific cautions in the cited label sections.
The recommended dosage of Vascepa is 4 grams per day, taken orally.
Label specifies the dosing regimen of 4 g/day (commonly 2 g capsules twice daily with meals).
Nausea and vomiting are the most common side effects of Vascepa.
Label lists GI adverse events but does not designate nausea/vomiting as the most common; no frequency ranking provided.
Abdominal pain is the most common side effect of Vascepa.
No statement indicating 'most common' abdominal pain in the cited label sections.
Diarrhea is the most common side effect of Vascepa.
Label does not declare diarrhea as the most common adverse effect in the cited sections.
Contradictions
Important Omissions
Contraindications and Boxed Warnings not addressed by the claims; verify label sections for contraindications and boxed warnings.
Importance:
Moderate
Pregnancy safety information not covered by the claims; verify label sections on pregnancy.
Importance:
Moderate
Pediatric use not addressed by the claims; verify label section on pediatric use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Bleeding risk is acknowledged in the label, particularly with concomitant anticoagulants/antiplatelet therapy; other common adverse events are GI-related and generally not severe. No new or unexpected safety signals identified from the evaluated claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Significant omissions identified (contraindications/boxed warnings, pregnancy, pediatric use).
Suggested Improvement
Incorporate complete label elements including contraindications and boxed warnings; provide pregnancy and pediatric guidance; avoid non-label assertions about long-term safety.